These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 18221875

  • 21. Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors.
    Dyckman AJ, Li T, Pitt S, Zhang R, Shen DR, McIntyre KW, Gillooly KM, Shuster DJ, Doweyko AM, Sack JS, Kish K, Kiefer SE, Newitt JA, Zhang H, Marathe PH, McKinnon M, Barrish JC, Dodd JH, Schieven GL, Leftheris K.
    Bioorg Med Chem Lett; 2011 Aug 01; 21(15):4633-7. PubMed ID: 21705217
    [Abstract] [Full Text] [Related]

  • 22. Synthesis and biological evaluation of substituted 1,2,3-benzotriazines and pyrido[3,2-d]-1,2,3-triazines as inhibitors of vascular endothelial growth factor receptor-2.
    Zhao XW, Liu D, Luan SL, Hu GD, Lv JL, Jing YK, Zhao LX.
    Bioorg Med Chem; 2013 Dec 15; 21(24):7807-15. PubMed ID: 24189187
    [Abstract] [Full Text] [Related]

  • 23. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities.
    Nie Z, Perretta C, Erickson P, Margosiak S, Lu J, Averill A, Almassy R, Chu S.
    Bioorg Med Chem Lett; 2008 Jan 15; 18(2):619-23. PubMed ID: 18055206
    [Abstract] [Full Text] [Related]

  • 24. SAR of a novel 'Anthranilamide Like' series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancer.
    Wickens P, Kluender H, Dixon J, Brennan C, Achebe F, Bacchiocchi A, Bankston D, Bierer D, Brands M, Braun D, Brown MS, Chuang CY, Dumas J, Enyedy I, Hofilena G, Hong Z, Housley T, Jones B, Khire U, Kreiman C, Kumarasinghe E, Lowinger T, Ott-Morgan R, Perkins L, Phillips B, Schoenleber R, Scott WJ, Sheeler R, Redman A, Sun X, Taylor I, Wang L, Wilhelm S, Zhang X, Zhang M, Sullivan E, Carter C, Miglarese M, Levy J.
    Bioorg Med Chem Lett; 2007 Aug 01; 17(15):4378-81. PubMed ID: 17574417
    [Abstract] [Full Text] [Related]

  • 25. Novel series of pyrrolotriazine analogs as highly potent pan-Aurora kinase inhibitors.
    Abraham S, Hadd MJ, Tran L, Vickers T, Sindac J, Milanov ZV, Holladay MW, Bhagwat SS, Hua H, Ford Pulido JM, Cramer MD, Gitnick D, James J, Dao A, Belli B, Armstrong RC, Treiber DK, Liu G.
    Bioorg Med Chem Lett; 2011 Sep 15; 21(18):5296-300. PubMed ID: 21802948
    [Abstract] [Full Text] [Related]

  • 26. Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.
    Brasca MG, Albanese C, Alzani R, Amici R, Avanzi N, Ballinari D, Bischoff J, Borghi D, Casale E, Croci V, Fiorentini F, Isacchi A, Mercurio C, Nesi M, Orsini P, Pastori W, Pesenti E, Pevarello P, Roussel P, Varasi M, Volpi D, Vulpetti A, Ciomei M.
    Bioorg Med Chem; 2010 Mar 01; 18(5):1844-53. PubMed ID: 20153204
    [Abstract] [Full Text] [Related]

  • 27. Exploration of acridine scaffold as a potentially interesting scaffold for discovering novel multi-target VEGFR-2 and Src kinase inhibitors.
    Luan X, Gao C, Zhang N, Chen Y, Sun Q, Tan C, Liu H, Jin Y, Jiang Y.
    Bioorg Med Chem; 2011 Jun 01; 19(11):3312-9. PubMed ID: 21576023
    [Abstract] [Full Text] [Related]

  • 28. Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.
    Wittman MD, Carboni JM, Yang Z, Lee FY, Antman M, Attar R, Balimane P, Chang C, Chen C, Discenza L, Frennesson D, Gottardis MM, Greer A, Hurlburt W, Johnson W, Langley DR, Li A, Li J, Liu P, Mastalerz H, Mathur A, Menard K, Patel K, Sack J, Sang X, Saulnier M, Smith D, Stefanski K, Trainor G, Velaparthi U, Zhang G, Zimmermann K, Vyas DM.
    J Med Chem; 2009 Dec 10; 52(23):7360-3. PubMed ID: 19778024
    [Abstract] [Full Text] [Related]

  • 29. Synthesis and evaluation of the antiproliferative activity of novel pyrrolo[1,2-a]quinoxaline derivatives, potential inhibitors of Akt kinase. Part II.
    Desplat V, Moreau S, Gay A, Fabre SB, Thiolat D, Massip S, Macky G, Godde F, Mossalayi D, Jarry C, Guillon J.
    J Enzyme Inhib Med Chem; 2010 Apr 10; 25(2):204-15. PubMed ID: 20222763
    [Abstract] [Full Text] [Related]

  • 30. Triazine and pyrimidine based ROCK inhibitors with efficacy in spontaneous hypertensive rat model.
    Ho KK, Beasley JR, Belanger L, Black D, Chan JH, Dunn D, Hu B, Klon A, Kultgen SG, Ohlmeyer M, Parlato SM, Ray PC, Pham Q, Rong Y, Roughton AL, Walker TL, Wright J, Xu K, Xu Y, Zhang L, Webb M.
    Bioorg Med Chem Lett; 2009 Nov 01; 19(21):6027-31. PubMed ID: 19800787
    [Abstract] [Full Text] [Related]

  • 31. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
    Li HY, McMillen WT, Heap CR, McCann DJ, Yan L, Campbell RM, Mundla SR, King CH, Dierks EA, Anderson BD, Britt KS, Huss KL, Voss MD, Wang Y, Clawson DK, Yingling JM, Sawyer JS.
    J Med Chem; 2008 Apr 10; 51(7):2302-6. PubMed ID: 18314943
    [Abstract] [Full Text] [Related]

  • 32. Metabolism of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737): identification of an unusual N-acetylglucosamine conjugate in the cynomolgus monkey.
    Johnson BM, Kamath AV, Leet JE, Liu X, Bhide RS, Tejwani RW, Zhang Y, Qian L, Wei DD, Lombardo LJ, Shu YZ.
    Drug Metab Dispos; 2008 Dec 10; 36(12):2475-83. PubMed ID: 18787055
    [Abstract] [Full Text] [Related]

  • 33. Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.
    Ruel R, Thibeault C, L'Heureux A, Martel A, Cai ZW, Wei D, Qian L, Barrish JC, Mathur A, D'Arienzo C, Hunt JT, Kamath A, Marathe P, Zhang Y, Derbin G, Wautlet B, Mortillo S, Jeyaseelan R, Henley B, Tejwani R, Bhide RS, Trainor GL, Fargnoli J, Lombardo LJ.
    Bioorg Med Chem Lett; 2008 May 01; 18(9):2985-9. PubMed ID: 18395443
    [Abstract] [Full Text] [Related]

  • 34. Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases.
    Mastalerz H, Chang M, Gavai A, Johnson W, Langley D, Lee FY, Marathe P, Mathur A, Oppenheimer S, Tarrant J, Tokarski JS, Vite GD, Vyas DM, Wong H, Wong TW, Zhang H, Zhang G.
    Bioorg Med Chem Lett; 2007 May 15; 17(10):2828-33. PubMed ID: 17368025
    [Abstract] [Full Text] [Related]

  • 35. Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1-f][1,2,4]triazines: identification of orally bioavailable, efficacious ALK inhibitors.
    Mesaros EF, Thieu TV, Wells GJ, Zificsak CA, Wagner JC, Breslin HJ, Tripathy R, Diebold JL, McHugh RJ, Wohler AT, Quail MR, Wan W, Lu L, Huang Z, Albom MS, Angeles TS, Wells-Knecht KJ, Aimone LD, Cheng M, Ator MA, Ott GR, Dorsey BD.
    J Med Chem; 2012 Jan 12; 55(1):115-25. PubMed ID: 22141319
    [Abstract] [Full Text] [Related]

  • 36. 4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.
    Zhang N, Wu B, Boschelli DH, Golas JM, Boschelli F.
    Bioorg Med Chem Lett; 2009 Sep 01; 19(17):5071-4. PubMed ID: 19632113
    [Abstract] [Full Text] [Related]

  • 37. Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors.
    Bauer D, Whittington DA, Coxon A, Bready J, Harriman SP, Patel VF, Polverino A, Harmange JC.
    Bioorg Med Chem Lett; 2008 Sep 01; 18(17):4844-8. PubMed ID: 18682324
    [Abstract] [Full Text] [Related]

  • 38. Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors.
    Kuo GH, Deangelis A, Emanuel S, Wang A, Zhang Y, Connolly PJ, Chen X, Gruninger RH, Rugg C, Fuentes-Pesquera A, Middleton SA, Jolliffe L, Murray WV.
    J Med Chem; 2005 Jul 14; 48(14):4535-46. PubMed ID: 15999992
    [Abstract] [Full Text] [Related]

  • 39. Discovery of pyrrolopyrimidine inhibitors of Akt.
    Blake JF, Kallan NC, Xiao D, Xu R, Bencsik JR, Skelton NJ, Spencer KL, Mitchell IS, Woessner RD, Gloor SL, Risom T, Gross SD, Martinson M, Morales TH, Vigers GP, Brandhuber BJ.
    Bioorg Med Chem Lett; 2010 Oct 01; 20(19):5607-12. PubMed ID: 20810279
    [Abstract] [Full Text] [Related]

  • 40. Discovery of novel taspine derivatives as antiangiogenic agents.
    Zhang J, Zhang Y, Zhang S, Wang S, He L.
    Bioorg Med Chem Lett; 2010 Jan 15; 20(2):718-21. PubMed ID: 20006929
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.